Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

illion (2006: $12.2 million). The increase in finance costs in 2007 over 2006 follows the acquisition of New River which was partly funded by $1.3 billion of term loans, utilized under Shire's $2.3 billion banking facility. These term loans were subsequently partially repaid using the proceeds from Shire's 2.75% convertible bond issued in May 2007. The remaining $200 million of the term loans was also repaid during the six months to June 30, 2007. Finance costs for the six months to June 30, 2007 include a $7.9 million write-off of deferred financing costs following the repayment of these term loans. Finance costs relating to the convertible bonds, representing interest expense, amortized discount and issue costs totaled $10.8 million for the six months to June 30, 2007.

In the six months to June 30, 2007 and 2006 finance costs included a provision for interest, which may be awarded by the Court in respect of amounts due to those ex-TKT shareholders who have requested appraisal of the acquisition consideration payable for their TKT shares. The original trial date for the appraisal rights litigation was set for April 23, 2007, but this trial date has since been postponed to May 2008.

Share of post tax profits from associates and joint ventures

Profits of $1.2 million were recorded for the six months to June 30, 2007 (2006: $4.3 million). This comprised profits of $3.1 million from the 50% share of the antiviral commercialization partnership with GSK in Canada (2006: $3.2 million), offset by losses of $1.9 million being Shire's share of losses in the GeneChem and EGS Healthcare Funds (2006: profit of $1.1 million).

Taxation

The effective rate of tax for the six months to June 30, 2007 was 77% (2006: 32%). The effective rate of tax in the six months to June 30, 2007 has increased over the six months to June 30, 2006 as a result of the inclusion in 2007 of non-deductible goodwill impairment charges totaling $80.9 million (2006: $nil). Exclu
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 BioStructures, LLC, a privately ... a milestone of 4,000 implantations of Signafuse® Bioactive ... in early 2014 as a bone void filler ... procedures.  This is a distinguished status among recently ... of new synthetic products have received clearance with ...
(Date:7/28/2015)... July 28, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... it has granted to German life sciences entrepreneurs ... and commercialization of biotechnology (collectively, the "Optionee"), an ... allogenic tumor vaccine technology (the "Technology"), including AEZS-120, ... which is ready to enter a Phase 1 ...
(Date:7/28/2015)... Israel , July 28, 2015 /PRNewswire/ ... regenerative medicine company utilizing its proprietary plant-based rhCollagen ... Shomrat Shurtz has been appointed Senior Director of ...      (Photo: http://photos.prnewswire.com/prnh/20150728/246955 ) , ... experience in marketing, regulatory and business strategy. Prior ...
(Date:7/27/2015)... 27, 2015  Amgen (NASDAQ: AMGN ) today ... results on Thursday, July 30, 2015, after the close ... followed by a conference call with the investment community ... Amgen will be Robert A. Bradway , chairman ... senior management team. Live audio of the ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3CollPlant Names Shomrat Shurtz Senior Director of Business Development 2Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
... 31 Revotar,Biopharmaceuticals AG., today announced first positive ... pilot study in 14 patients with,stable COPD stage ... of Bimosiamose,twice a day. The study was conducted ... Witt and the Respiratory Institute Wiesbaden, Dr.,Beeh. The ...
... Oct. 31 Amedica Corporation,an orthopedic implants company ... the U.S. Food and Drug Administration,has granted 510(k) ... The Valeo(TM) Cervical Plate system combines features aimed ... The,Valeo(TM) Cervical Plate system is intended for anterior ...
... Md., Oct. 31 Micromet, Inc.,(Nasdaq: MITI ... of,novel, proprietary antibody-based products for cancer, inflammation and,autoimmune ... and,Chief Executive Officer of Micromet, will present at ... Conference in New York, on,Wednesday, November 7, 2007 ...
Cached Biology Technology:Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD 2Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007 2
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... is participating in a large-scale, multi-center clinical trial in ... substance, in high doses, can slow the progression of ... million people in the United States. "At present, ... only mask the symptoms they do not alter ...
... have found the "Rosetta Stone" of supervolcanoes, those giant ... massive explosive eruptions that rank among nature,s most violent ... and possibly trigger climatic and environmental effects at ... discovered in the Italian Alps, Sesia Valley by a ...
... 100 billion (1011) neurons, which altogether form about 100 ... mechanism for the generation of this complex wiring pattern ... Hannes Schmidt and Professor Fritz G. Rathjen at the ... have now discovered a molecule that regulates this vital ...
Cached Biology News:Can an over-the-counter vitamin-like substance slow the progression of Parkinson's disease? 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 2'Rosetta Stone' of supervolcanoes discovered in Italian Alps 3MDC researchers discover molecule responsible for axonal branching 2
... Source rat adult and fetal ... $550.00, * T75 plated cells ... * This product requires Celprogen ... M55007-08 and extracellular matrix, * ...
... is a K-12 strain ideally suited as ... high transformation efficiency, blue/white screening capability (with ... result in high yields of excellent quality ... is potentially useful as a stringent host ...
... Purification with an Affinity Chitin-binding Tag) utilizes ... splicing elements (termed inteins) to purify recombinant ... (Figures 1 and 2). This system distinguishes ... its ability to separate a recombinant protein ...
... imaging system from Molecular Devices ... system for automated acquisition and analysis ... screening. ImageXpressULTRA is powered by ... screening acquisition, image storage and analysis. ...
Biology Products: